DYRK1A and Denys-Drash syndrome: Therefore, we performed Western blot analyses using the D1694 antibody targeting the N-terminal region of the protein DYRK1A (Figure 2a) and observed a decreased level of the full-length form of DYRK1A with an increased level of the truncated form (50 kDa) in LCLs of patients with dDS compared to the level in LCLs from individuals with aDS (317 ± 37 vs. 214 ± 22) (Figure 2b,d), the level of this truncated form being increased in LCLs of patients with aDS compared to the level in LCLs from euploid healthy individuals (214 ± 22 vs. 100 ± 15 (Figure 2d).